Prelude Capital Management’s Royalty Pharma RPRX Stock Holding History

Prelude Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$631K	Buy	+13,145	New	+$576K	0.05%	425
2025 Q3	–	Sell	-26,812	Closed	-$966K	–	1342
2025 Q2	$966K	Buy	26,812 +971	+4%	+$32.2K	0.09%	267
2025 Q1	$804K	Buy	+25,841	New	+$819K	0.06%	362
2024 Q2	–	Sell	-22,866	Closed	-$694K	–	1457
2024 Q1	$694K	Buy	+22,866	New	+$674K	0.04%	499
2023 Q3	–	Sell	-15,944	Closed	-$490K	–	1323
2023 Q2	$490K	Buy	15,944 +944	+6%	+$32K	0.03%	470
2023 Q1	$540K	Hold	15,000	–	–	0.03%	436
2022 Q4	$593K	Buy	+15,000	New	+$626K	0.03%	506
2022 Q2	–	Sell	-9,131	Closed	-$356K	–	2021
2022 Q1	$356K	Buy	+9,131	New	+$359K	0.01%	1004
2021 Q4	–	Sell	-6,560	Closed	-$237K	–	2214
2021 Q3	$237K	Buy	+6,560	New	+$255K	0.01%	1266

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Prelude Capital Management's RPRX Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Royalty Pharma (RPRX) in Q1 2026: 13,145 shares worth $631K. The stake represents 0.05% of the portfolio and ranks #425 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in RPRX as recently as Q2 2025.

Prelude Capital Management first reported a position in RPRX in Q3 2021 and has held it in 9 quarters since. The position peaked at $966K in Q2 2025. 588 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Prelude Capital Management held 13,145 shares of Royalty Pharma worth $631K as of Q1 2026.
Royalty Pharma was a new Prelude Capital Management position in Q1 2026.
Royalty Pharma made up 0.05% of Prelude Capital Management's portfolio in Q1 2026, its #425 holding.
Prelude Capital Management first reported a position in Royalty Pharma in Q3 2021 and has held it in 9 quarters since.
Prelude Capital Management's Royalty Pharma position peaked at $966K in Q2 2025.
588 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.